{"pmid":32462329,"title":"Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.","text":["Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with COVID-19.","Ann Hematol","Albiol, Nil","Awol, Rahinatu","Martino, Rodrigo","32462329"],"journal":"Ann Hematol","authors":["Albiol, Nil","Awol, Rahinatu","Martino, Rodrigo"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462329","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00277-020-04097-0","topics":["Case Report"],"weight":1,"_version_":1668079521463533568,"score":9.490897,"similar":[{"pmid":32294340,"pmcid":"PMC7179995","title":"Immune Thrombocytopenic Purpura in a Patient with Covid-19.","text":["Immune Thrombocytopenic Purpura in a Patient with Covid-19.","N Engl J Med","Zulfiqar, Abrar-Ahmad","Lorenzo-Villalba, Noel","Hassler, Patrick","Andres, Emmanuel","32294340"],"journal":"N Engl J Med","authors":["Zulfiqar, Abrar-Ahmad","Lorenzo-Villalba, Noel","Hassler, Patrick","Andres, Emmanuel"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32294340","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1056/NEJMc2010472","topics":["Case Report"],"weight":1,"_version_":1666138494351704065,"score":61.973495},{"pmid":32441787,"title":"A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","text":["A Rare Case of Immune Thrombocytopenic Purpura Secondary to COVID-19.","Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi","32441787"],"abstract":["Coronavirus Disease 2019 (COVID-19) is a newly emerging infectious disease caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). After its first occurrence in Wuhan of China from December 2019, COVID-19 rapidly spread around the world. Studies have shown that coagulation dysfunction is one of the important reason causing death of COVID-19 patients and appeared in many patients. However, cases of COVID-19 with immune thrombocytopenic purpura were very rare. Here, a patient with immune thrombocytopenic purpura in Huoshenshan Hospital (Wuhan, China) was reported, whose laboratory data, clinical treatment and hospital outcome was described in this study. Fortunately, immune thrombocytopenic purpura with COVID-19 of the patient was diagnosed and treated in time and cured eventually. This case illustrates the need to be vigilant for complications associated with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Yang, Yang","Zhao, Jun","Wu, Jian","Teng, Yi","Xia, Xinyi"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441787","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26051","keywords":["coronavirus < virus classification","disease control","immune responses"],"locations":["Wuhan","China","Huoshenshan Hospital","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1667523504786898945,"score":56.650284}]}